-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Pdg0fW/+zrYQ8SfTnlhfGmZSGj3S1nM7Wpgtkqxr1RCX4LNEvCqDXWwBH5MqDAmr DH1++W/XAeK0BaBD+KQzXw== 0000203077-97-000006.txt : 19971114 0000203077-97-000006.hdr.sgml : 19971114 ACCESSION NUMBER: 0000203077-97-000006 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19970930 FILED AS OF DATE: 19971112 SROS: NYSE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ST JUDE MEDICAL INC CENTRAL INDEX KEY: 0000203077 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411276891 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: SEC FILE NUMBER: 001-12441 FILM NUMBER: 97712318 BUSINESS ADDRESS: STREET 1: ONE LILLEHEI PLAZA CITY: ST PAUL STATE: MN ZIP: 55117 BUSINESS PHONE: 6124832000 MAIL ADDRESS: STREET 1: ONE LILLEHEI PLAZA CITY: ST PAUL STATE: MN ZIP: 55117 10-Q 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended September 30, 1997 Commission File Number 0-8672 ------------------ ------ ST. JUDE MEDICAL, INC. (Exact name of registrant as specified in its charter) MINNESOTA 41-1276891 - ---------------------------------- ------------------------------------ (State or other jurisdiction (I.R.S. Employer Identification No.) of incorporation or organization) One Lillehei Plaza, St. Paul, Minnesota 55117 --------------------------------------------------------- (Address of principal executive offices) (612) 483-2000 ---------------------------------------------------- (Registrant's telephone number, including area code) Not Applicable --------------------------------------------------------------------- (Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. YES __X__ NO ____ The number of shares of common stock, par value $.10 per share, outstanding at November 6, 1997 was 91,874,119. This Form 10-Q consists of _______ pages consecutively numbered. The Exhibit Index to this Form 10-Q is set forth on page _________. PART I FINANCIAL INFORMATION ST. JUDE MEDICAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Dollars in thousands, except per share amounts) NOTE 1 - BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information, and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 1997 are not necessarily indicative of the results that may be expected for the full year ended December 31, 1997. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 1996. NOTE 2 - ACQUISITIONS/DIVESTITURE Effective May 15, 1997, the Company acquired Ventritex, Inc., a Sunnyvale, California based manufacturer of implantable cardioverter defibrillators and related products. Each share of Ventritex common stock was converted into .5 shares of St. Jude Medical common stock. The Company issued 10,437,800 shares to Ventritex shareholders. The transaction was accounted for as a pooling of interests. The accompanying financial statements, for all periods presented, are presented on a pooled basis. The results of Ventritex's operations have been included in the condensed consolidated results of operations as if the merger had occurred at the beginning of 1996. These results are not necessarily indicative of the results that would have occurred had the merger actually taken place at the beginning of 1996, or of the expected future results of operations. On November 29, 1996, the Company acquired from Pacific Dunlop, Ltd. substantially all of the worldwide cardiac rhythm management assets of Telectronics Pacing Systems, Inc. ("Telectronics") for $135,000. The acquisition was accounted for under the purchase accounting method. The initial price can be adjusted upward or downward based upon the change in net asset value between June 30, 1996 and November 29, 1996. The Company and Pacific Dunlop, Ltd. currently disagree about the final adjustment to the purchase price and are following procedures in the purchase agreement to resolve their differences. The Company expects that any adjustment to the purchase price would be recorded in 1997 as an adjustment to goodwill. Goodwill of approximately $76,000 including approximately $43,000 of consolidation charges, is being amortized on a straight line basis over 20 years. Telectronics operations have been included in the consolidated results of operations from the date of acquisition. PART I FINANCIAL INFORMATION (continued) The following unaudited pro forma summary information presents the results of operations of the Company and Telectronics for the nine months ended September 30, 1996, as if the acquisition had occurred at the beginning of 1996. Nine Months Ending September 30 1996 (Unaudited) ------------- Net sales $ 715,699 Net (loss) $ (11,585) Primary (loss) per share $ (.13) These pro forma results are not necessarily indicative of the results that would have occurred had the acquisition actually taken place at the beginning of 1996, or of the expected future results of the combined operations. On August 29, 1997, the Company sold Medtel, a Far East distribution company, to Getz Brothers and Co., Inc. The gain on the sale of this business was recorded as an adjustment to previously recorded goodwill. The results of operations of Medtel were not material to the consolidated results. NOTE 3 - CONTINGENCIES The Company is involved in various products liability lawsuits, claims and proceedings of a nature considered normal to its business. In connection with two pacemaker lead models, the Company may be subject to future uninsured claims. The Company's products liability insurance carrier has denied coverage for these models and has filed suit against the Company seeking rescission of the policy covering Pacesetter business retroactive to the date the Company acquired Pacesetter. The Company was a codefendant in a 1995 class action suit with respect to these leads. This case was settled in November 1995. The Company's share of the settlement is approximately $5,000. This case is more fully described in Item I Part II of this Quarterly Report on Form 10-Q. Additional claims could be filed by patients with these leads who were not class members. Further, claims may be filed in the future relative to events currently unknown to management. Management believes losses that might be sustained from such actions would not have a material adverse effect on the Company's liquidity or financial condition, but could potentially be material to the net income of a particular future period if resolved unfavorably. PART I FINANCIAL INFORMATION (continued) NOTE 4 - STATEMENT OF FINANCIAL ACCOUNTING STANDARDS NO. 128, EARNINGS PER SHARE In February 1997, the Financial Accounting Standards Board issued Statement No. 128, EARNINGS PER SHARE, which is required to be adopted for all financial statements issued for periods ending after December 15, 1997. At that time, the Company will be required to change the method currently used to compute earnings per share and to restate all prior periods. Under the new requirements for calculating basic earnings per share, the dilutive effect of stock options will be excluded. The impact is expected to result in an increase in basic earnings per share of $.01 per share for the year-to-date amounts for both years presented and no change for the third quarter for both years presented. NOTE 5 - STATEMENT OF FINANCIAL STANDARDS NO. 130, REPORTING COMPREHENSIVE INCOME In June 1997, the Financial Accounting Standards Board issued Statement No. 130, Reporting Comprehensive Income, which is required to be adopted for all financial statements issued for periods beginning after December 15, 1997. At that time the Company will be required to separately report the amounts (and the related tax effect) classified as Other Comprehensive Income. Items recorded as a separate component of equity such as foreign currency translation gains/losses and unrealized gains/losses on certain investments in debt and equity securities are included in Other Comprehensive Income. NOTE 6 - DERIVATIVE FINANCIAL INSTRUMENTS In January 1997, the SEC issued new rules related to disclosures about derivative financial instruments. The new rules, effective for all financial statements issued for periods ending after June 15, 1997, require enhanced accounting policy disclosures regarding derivative financial instruments in the financial statements and for periods ending after June 15, 1998, qualitative and quantitative information about all financial instruments should be disclosed outside the financial statements and related notes. The Company has entered into readily marketable forward and option traded contracts to manage its exposure to fluctuations in foreign currency exchange rates. This hedging minimizes the impact of foreign exchange rate movements on the Company's operating results. These contracts involve the exchange of foreign currencies for U.S. dollars at specified rates at future dates. The changes in market value of such contracts have a high correlation to the price changes in the currency of the related hedged transaction. These contracts are recorded at fair value and gains or losses are included in other income (expense). NOTE 7 - SPECIAL CHARGE UPDATE The Company's special charge accruals of $47,808 and $30,645 recorded in the fourth quarter of 1996 and the second quarter of 1997 have decreased by $37,639 and $12,026, respectively, for cash payments since the date recorded. PART I FINANCIAL INFORMATION (continued) ST. JUDE MEDICAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts in thousands, except per share amounts) (Unaudited)
THREE MONTHS NINE MONTHS ENDED ENDED SEPTEMBER 30 SEPTEMBER 30 ------------------------- ------------------------ 1997 1996 1997 1996 ---- ---- ---- ---- Net sales $ 233,189 $ 212,456 $ 745,035 $ 644,783 Cost of sales 88,766 69,464 272,114 213,063 ---------- ---------- ---------- ---------- Gross profit 144,423 142,992 472,921 431,720 Selling, general & administrative 88,365 72,321 282,778 225,503 Research & development 26,304 25,970 84,189 77,801 Purchased research & development -- -- -- 5,000 Special charges -- -- 30,645 -- ---------- ---------- ---------- ---------- Operating profit 29,754 44,701 75,309 123,416 Other income (expense) (1,103) 1,209 2,210 13,489 ---------- ---------- ---------- ---------- Income before taxes 28,651 45,910 77,519 136,905 Income tax provision 10,099 15,731 27,325 46,748 ---------- ---------- ---------- ---------- Net income $ 18,552 $ 30,179 $ 50,194 $ 90,157 ========== ========== ========== ========== Earnings per share: Primary $ .20 $ .33 $ .54 $ .98 ========== ========== ========== ========== Fully diluted $ .20 $ .33 $ .54 $ .98 ========== ========== ========== ========== Shares outstanding Primary 93,251 92,421 92,856 92,200 Fully diluted 93,251 92,814 93,053 92,331
See notes to condensed consolidated financial statements. PART I FINANCIAL INFORMATION (continued) ST. JUDE MEDICAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except per share amounts)
SEPTEMBER 30 DECEMBER 31 1997 1996 (UNAUDITED) (SEE NOTE) ------------ ------------ ASSETS Current assets: Cash and cash equivalents $ 22,311 $ 49,388 Marketable securities 149,601 186,007 Accounts receivable, less allowance (1997 - $7,776; 1996 - $8,160) 247,654 216,813 Inventories Finished goods 139,207 119,736 Work in process 39,053 30,227 Raw materials 61,797 67,698 ------------ ------------ Total inventories 240,057 217,661 Other current assets 71,033 78,015 ------------ ------------ Total current assets 730,656 747,884 Property, plant and equipment 455,446 397,674 Less accumulated depreciation (142,621) (108,400) ------------ ------------ Net property, plant and equipment 312,825 289,274 Other assets 423,155 435,336 ------------ ------------ TOTAL ASSETS $ 1,466,636 $ 1,472,494 ============ ============ LIABILITIES & SHAREHOLDERS' EQUITY Accounts payable and accrued expenses $ 257,812 $ 320,933 Long-term debt 229,500 229,500 Contingencies Shareholders' equity: Preferred stock, par value $1.00 per share - 25,000,000 shares authorized; no shares issued Common stock, par value $.10 per share - 250,000,000 shares authorized; issued and outstanding 1997 - 91,823,047 shares; 1996 - 91,404,961 shares 9,182 9,140 Additional paid-in capital 241,131 228,111 Retained earnings 743,086 692,892 Cumulative translation adjustment (26,125) 386 Unrealized gain/(loss) on available-for-sale securities 12,050 (8,028) Receivable - stock issued -- (440) ------------ ------------ Total shareholders' equity 979,324 922,061 ------------ ------------ TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $ 1,466,636 $ 1,472,494 ============ ============
NOTE: The balance sheet at December 31, 1996 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. See notes to condensed consolidated financial statements. ST. JUDE MEDICAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands) (Unaudited)
NINE MONTHS ENDED SEPTEMBER 30 ------------------------- 1997 1996 ---- ---- Operating Activities: Net income $ 50,194 $ 90,157 Depreciation and amortization 51,132 42,920 Purchased research and development -- 5,000 Special charges 19,104 -- Gain on sale of business -- (10,486) Working capital change (189,324) (40,779) ---------- ---------- Net cash provided (used) by operating activities (68,894) 86,812 ---------- ---------- Investment Activities: Purchases of property, plant and equipment (65,818) (63,204) Sales (purchases) of available-for-sale securities, net 73,595 (470) Acquisitions, net of cash acquired -- (7,430) Proceeds from sale of business, net of cash disposed 24,626 24,204 Other investing activities (2,729) (5,127) ---------- ---------- Net cash provided by (used in) investing activities 29,674 (52,027) ---------- ---------- Financing Activities: Proceeds from exercise of stock options 13,062 22,893 Repayment of long-term debt -- (120,000) Proceeds from issuance of convertible subordinated notes -- 57,500 Proceeds from receivable for stock issued 440 -- ---------- ---------- Net cash used in financing activities 13,502 (39,607) ---------- ---------- Effect of currency exchange rate changes on cash (1,359) (151) ---------- ---------- Decrease in cash and cash equivalents (27,077) (4,973) Cash and cash equivalents at beginning of year 49,388 62,638 ---------- ---------- Cash and cash equivalents at end of period $ 22,311 $ 57,665 ========== ==========
See notes to condensed consolidated financial statements. MANAGEMENT DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION (Dollars in thousands, except per share amounts) RESULTS OF OPERATIONS: NET SALES. Net sales for the third quarter 1997 totaled $233,189, a $20,733 or 9.8% increase over the 1996 third quarter net sales. Excluding Telectronics and Far East distribution of other products net sales of approximately $16,000, third quarter net sales were about 2.0% higher than the prior year comparable period. For the first nine months, net sales totaled $745,035, a $100,252 or 15.5% increase over the net sales recorded in the first nine months of 1996. Excluding Telectronics and Far East distribution of other products net sales of approximately $72,000, the first nine months 1997 net sales increased about 4.4% over the first nine months of 1996. Unfavorable foreign currency effects due to the stronger U.S. dollar reduced 1997 net sales as compared to 1996 by approximately $8,700 and $18,800 for the quarter and first nine months, respectively. Third quarter and the first nine months net sales increased primarily due to higher mechanical heart valve, tissue heart valve, implantable cardioverter defibrillator, electrophysiology catheter and bradycardia pulse generator and lead unit sales that were partially offset by lower average selling prices. Average selling prices decreased because of pricing pressures, unfavorable foreign currency effects of a stronger U.S. dollar and more units being sold into lower priced developing markets. GROSS PROFIT. Third quarter 1997 gross profit totaled $144,423, or 61.9% of net sales, as compared to $142,992, or 67.3% of net sales during the comparable 1996 period. For the first nine months of 1997 and 1996, gross profit was $472,921 or 63.5% of net sales, and $431,720, or 67.0% of net sales, respectively. The lower 1997 gross profit margin for both the quarter and year-to-date resulted from the foreign currency impact on net sales, average selling price decreases due to higher sales into developing markets, pricing pressures in the cardiac rhythm management business and the inclusion of Telectronics in the 1997 results. SELLING GENERAL & ADMINISTRATIVE. Selling General and Administrative (SG&A) expenses in the third quarter 1997 of $88,365 increased $16,044, or 22.2% over the third quarter of 1996. As a percentage of sales, 1997 SG&A increased to 37.9% from 34.0% in 1996. On a year-to-date basis, 1997 SG&A expenses totaled $282,778, a $57,275, or 25.4% increase over 1996. The increases for both the quarter and first nine months resulted from the inclusion of Telectronics in 1997, expenses for expanded sales and marketing organizations in the emerging markets of Latin America, Asia Pacific and Canada, and expenses for and enhancing information technology and communications systems. PART I MANAGEMENT DISCUSSION & ANALYSIS (continued) RESEARCH AND DEVELOPMENT. Research and Development (R&D) expenses in the third quarter of 1997 totaled $26,304, a $334 increase over the third quarter of 1996. The first nine months of 1997 R&D expenses totaled $84,189, a $6,388 increase over the 1996 comparable period. The increase for both the quarter and the first nine months was attributable to the inclusion of Telectronics in 1997 which was partially offset by the completion of certain Ventritex projects. PURCHASED RESEARCH & DEVELOPMENT. The $5,000 non-cash 1996 charge related to purchased Research & Development (R&D) in connection with the acquisition of the Heart Valve Company. This represents the appraised value of in-process R&D which must be expensed under generally accepted accounting principles for purchase accounting. SPECIAL CHARGES. In the second quarter 1997, the Company recorded $30,645 of special charges related to the Ventritex merger which consisted of transaction charges of $8,227, U.S. distribution reorganization charges of $9,433, repositioning charges of $6,939 related to its tachycardia business and integration charges of $6,046. OTHER INCOME/(EXPENSE). Other expense in the third quarter 1997 totaled $1,103 compared to other income of $1,209 in the third quarter of 1996. For the first nine months of 1997 other income totaled $2,210 versus $13,489 in the comparable period of 1996. Interest expense in the third quarter 1997 increased by approximately $3,100 over the third quarter of 1996. The increase was due to the higher debt level associated with the Telectronics acquisition and the assumption of the Ventritex convertible debenture which was issued in the third quarter of 1996. In the third quarter 1997, gains on the sale of investments increased by almost $1,600 over the third quarter 1996. On a year-to-date basis, several non-recurring 1996 transactions increased other income over 1997 levels, including a $10,486 gain on the sale of the cardiac assist business, a $2,951 gain as a result of the successful completion of litigation related to a termination fee in connection with the Electromedics acquisition less $5,500 of transaction costs associated with the Daig acquisition. INCOME TAX PROVISION. The Company's 1997 effective income tax rate was 35.25% compared to 34.15% in 1996. The increase was due to the non-deductibility of certain transaction costs related to the Ventritex acquisition and changes to the Internal Revenue Code (IRC) Section 936 regulations that were finalized during the second quarter of 1996. These regulations reduced the tax benefits derived from the Company's Puerto Rican operations. PART I MANAGEMENT DISCUSSION & ANALYSIS (continued) OUTLOOK. The Company expects that market demands, government regulation and societal pressures will continue to change the healthcare industry worldwide resulting in further business consolidations and alliances and pressure to reduce prices and product purchases. To meet customer needs, the Company intends to continue to broaden its product offerings through internal development or external diversification opportunities. For the balance of 1997, however, management intends to concentrate its efforts on the integration of Telectronics and Ventritex into its Cardiac Rhythm Management business. In addition, the Company will participate with industry groups to promote the introduction and use of advanced medical device technology within a cost conscious environment. Finally, customer service in the form of cost-effective clinical outcomes will continue to be a primary focus for the Company. As provided for in the Private Securities Litigation Reform Act of 1995, the Company cautions investors that a number of factors could cause actual future results of operations to vary from those anticipated in any forward-looking statements made in this document and elsewhere by or on behalf of the Company. Net sales could be materially affected by legislative or administrative reforms to the U.S. Medicare and Medicaid systems in a manner that would significantly reduce reimbursement for procedures using the Company's medical devices, the acquisition of key patents by competitors that would have the effect of excluding the Company from new market segments, healthcare industry consolidation resulting in customer demands for price concessions, products introduced by competitors with advanced technology and better features and benefits or lower prices, fewer procedures performed in a cost conscious environment, and the lengthy approval time by the FDA to clear implantable medical devices for commercial release. Cost of sales could be materially affected by unfavorable developments in the area of products liability and price increases from the Company's suppliers of critical components, a number of which are sole sourced. Operations could be affected by the Company's ability to integrate acquired companies, to effectively implement its strategy of selling products from acquired companies through its existing sales distribution network, a serious earthquake affecting the Company's facilities in California, adverse developments in the litigation arising from the acquisitions of Telectronics and Ventritex, including litigation related to the Ventritex Cadence model V-110 ICD device, unanticipated product failures and attempts by competitors to gain market share through aggressive marketing programs. The Company's 1997 effective income tax rate increased from 1996 due to non-deductible transaction costs related to the Ventritex transaction, reduced Puerto Rican income as a percentage of total income and a lower Puerto Rican tax benefit as IRC Section 936 tax benefits are reduced by an additional 5% per year through 1998. Legislation was also passed in 1996 to phase out the Section 936 tax benefit over a ten year period which will further negatively impact the Company's effective tax rate. In addition, the IRS issued a Notice of Deficiency of $16,353 in additional taxes relating primarily to the Company's Puerto Rican operations in 1990 and 1991. It is likely that similar assessments will be proposed for subsequent years. The Company filed a petition in Tax Court in June 1997 contesting the full amount of the deficiency. PART I MANAGEMENT DISCUSSION & ANALYSIS (continued) FINANCIAL CONDITION The Company's financial condition at September 30, 1997, continues to remain strong. Long-term debt of $229,500 was unchanged from the prior year end balance. The ratio of current assets to current liabilities was 2.8 to 1 at September 30, 1997. Total assets decreased $5,858 during the first nine months of 1997. Accounts receivable increased $30,841 due to a higher sales level particularly in emerging markets which have extended credit terms. Inventories increased $22,396 due to expanded product offerings. Cash and marketable securities decreased $63,483 primarily to fund the operations of Telectronics and Ventritex and the reduction of accrued liabilities. Shareholders' equity increased $57,263 during the first nine months of 1997. The increase resulted from net income of $50,194, the exercise of stock options of $13,062, a net unrealized gain on investments of $20,078 and the repayment of a stock receivable of $440 less a foreign currency translation adjustment of $26,511. PART II OTHER INFORMATION Item 1. LEGAL PROCEEDINGS GUIDANT LITIGATION On November 26, 1996, Guidant Corporation ("Guidant"), a competitor of Pacesetter and Ventritex, CPI (a wholly owned subsidiary of Guidant), Guidant Sales Corporation (a wholly owned subsidiary of CPI),( "GSC"), and Eli Lilly and Company (the former owner of CPI), ("Lilly") (collectively, the "Guidant Parties"), filed a lawsuit against St. Jude Medical, Inc., Pacesetter Inc. ("Pacesetter"), Ventritex Inc. ("Ventritex") and certain members of the Telectronics Group in State Superior Court in Marion County, Indiana (the "Telectronics Action"). The lawsuit alleges, among other things, that, pursuant to an agreement entered into in 1993, CPI and Lilly granted Ventritex certain intellectual property licenses relating to cardiac stimulation devices, and that such licenses will terminate upon consummation of the merger of Ventritex into Pacesetter (the "Merger"). The lawsuit further alleges that, pursuant to an agreement entered into in 1994 (the "Telectronics Agreement"), CPI and Lilly granted the Telectronics Group certain intellectual property licenses relating to cardiac stimulation devices (the "CPI/Telectronics License"). The lawsuit seeks declaratory and injunctive relief, among other things, to prevent and invalidate the transfer of the Telectronics Agreement to Pacesetter in connection with Pacesetter's acquisition of Telectronic's assets (the "Telectronics Acquisition") and the application of license rights granted under the Telectronics Agreement to the manufacture and sale by Pacesetter of Ventritex's products following the consummation of the Merger. On December 17, 1996, St. Jude Medical, Pacesetter, Ventritex and the Telectronics Group removed the lawsuit to the United States District Court for the Southern District of Indiana, and filed a motion to dismiss the complaint or, in the alternative, to stay proceedings pending arbitration of the dispute pursuant to the arbitration provisions of the Telectronics Agreement. On January 16, 1997, the Guidant Parties filed a motion to remand the lawsuit to state court which was granted in May 1997. St. Jude Medical, Pacesetter and Ventritex filed a motion in state court to dismiss the complaint or, in the alternative, to stay the proceedings pending arbitration. This motion was denied by the court on July 21, 1997. St. Jude Medical and Pacesetter are continuing to vigorously defend the claims which the Guidant Parties have asserted in this action. PART II OTHER INFORMATION (continued) CPI, GSC and Lilly (collectively the "Guidant Parties") simultaneously filed suit against St. Jude Medical, Pacesetter and Ventritex in the United States District Court for the Southern District of Indiana seeking (i) a declaratory judgment that the manufacture, use or sale of cardiac stimulation devices of the type or similar to the type currently manufactured and sold by Ventritex will, upon consummation of the Merger, be unlicensed and constitute an infringement of patent rights owned by CPI and Lilly, (ii) to enjoin the manufacture, use or sale by St. Jude Medical, Pacesetter or Ventritex of cardiac stimulation devices of the type currently manufactured by Ventritex and (iii) certain damages and costs. On December 19, 1996, St. Jude Medical, Pacesetter and Ventritex filed a motion to dismiss the complaint or, in the alternative, to stay proceedings pending resolution of the Telectronics Action or arbitration. The court denied this motion. St. Jude Medical and Pacesetter are continuing to vigorously defend against the claims which the Guidant Parties asserted in this action. St. Jude Medical believes that the foregoing complaints contain a number of significant factual inaccuracies concerning the Telectronics Acquisition and the terms and effects of the various intellectual property license agreements referred to in such complaints. St. Jude Medical and Pacesetter believe that the allegations set forth in the complaints are without merit, and St. Jude Medical and Pacesetter intend to defend the actions vigorously. On December 24, 1996, the Telectronics Group and Pacesetter filed a lawsuit and a motion against the Guidant Parties in the United States District Court for the District of Minnesota seeking (i) a declaratory judgment that the Defendants' claims, as reflected in the Telectronics Action, are subject to arbitration pursuant to the arbitration provisions of the Telectronics Agreement, (ii) an order that the Defendants arbitrate their claims against the Telectronics Group and Pacesetter in accordance with the arbitration provisions of the Telectronics Agreement, (iii) to enjoin the Defendants preliminarily and permanently from litigating their dispute with the Telectronics Group and Pacesetter in any other forum and (iv) certain costs. On February 27, 1997, the court entered an order denying the Telectronics Group's and Pacesetter's motion and dismissing their complaint. On March 27, 1997, the Telectronics Group and Pacesetter filed a Notice of Appeal from the court's February 27, 1997 order. PART II OTHER INFORMATION (continued) OTHER LITIGATION AND PROCEEDINGS From 1987 to 1991, Siemens AG, through its Pacesetter and other affiliates, manufactured and sold approximately 32,000 model 1016T and 1026T pacemaker leads, of which approximately 25,000 were sold in the United States. In March 1993, Siemens was sued in federal district court in Cincinnati, Ohio (the "Wilson case"). The suit alleged that the model 1016T leads were negligently designed and manufactured. Class action status was granted by the court in September 1993. When St. Jude Medical acquired Pacesetter from Siemens on September 30, 1994, the purchase agreement specifically provided that Siemens retain all liability for the Wilson case, as well as all other litigation that was pending or threatened before October 1, 1994. The purchase agreement also provided that St. Jude Medical would assume liability for other product liability claims which arose after September 30, 1994. Siemens and St. Jude Medical were named defendants in a class action suit filed in March 1995 in federal district court in Houston, Texas for alleged defects in models 1016T and 1026T pacing leads (the "Hann case"). The suit sought class action status for patients who had inner insulation failures of these leads after March 22, 1993 and who were not members of the Wilson case class. Siemens and St. Jude Medical settled the Wilson and Hann cases in November 1995. Management currently estimates the Company's share of the settlement to be approximately $5 million; however, the precise number of class members, and the corresponding financial liability, could increase or decrease as the process for filing claims is completed. The settlement agreement has an "opt out" provision for class members. Apart from this class action settlement, additional claims could be made or lawsuits brought by patients with these leads whose leads fail at a later date or whose leads fail for reasons outside the class definition. St. Jude Medical's products liability insurance carrier, Steadfast, a wholly owned subsidiary of Zurich Insurance Company ("Zurich"), has denied coverage for these cases and has filed suit against St. Jude Medical in federal district court in Minneapolis, Minnesota seeking rescission of the policy covering Pacesetter business retroactive to the date St. Jude Medical acquired Pacesetter. Zurich alleges that St. Jude Medical made material negligent misrepresentations to Zurich, including failure to disclose the Wilson case in order to procure the insurance policy. St. Jude Medical has filed an answer denying Zurich's claim and has alleged that Zurich specifically had knowledge of the Wilson case. The terms of the products liability insurance policy which Zurich is seeking to rescind provide that St. Jude Medical would be entitled to $10 million in coverage for the 1016T and 1026T pacemaker lead claims after payment by St. Jude Medical of a self insured retention. In connection with these proceedings, St. Jude Medical has filed suit against its former insurance broker, Johnson & Higgins. Discovery has been completed and the case is ready for trial. PART II OTHER INFORMATION (continued) Item 6. EXHIBITS and REPORTS ON FORM 8-K (a) Exhibits Exhibit Number Exhibit ------ ------- 2 Not applicable 3(ii) By-laws 4 Rights Agreement dated as of July 16, 1997 between the Company and American Stock Transfer and Trust Company, as Rights Agent including Certificate of Designation, Preferences and Rights of Series B Junior Preferred Stock is incorporated by reference to Exhibit 4 of the Registrant's Form 10Q dated as of August 12, 1997. 10 Not applicable 22 Not applicable 23 Not applicable 24 Not applicable 27 Financial Data Schedule (b) Form 8-k dated August 6, 1997. Item 5. Other Events Announcement of the Rights Agreement dated as of July 16, 1997, between the Company and American Stock Transfer and Trust Company, as Rights Agent including Certificate of Designation, Preferences and Rights of Series B Junior Preferred Stock. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed in its behalf by the undersigned thereunto duly authorized. ST. JUDE MEDICAL, INC. November 10, 1997 /s/ ROBERT E. MUNZENRIDER - --------------------- ----------------------------------- DATE ROBERT E. MUNZENRIDER Vice President - Finance and Chief Financial Officer (Principal Financial and Accounting Officer) EX-3.(II) 2 BYLAWS Item 6 (a) Exhibits Exhibit 3 (ii) By-Laws BYLAWS OF ST. JUDE MEDICAL, INC.* ARTICLE I Shareholders Section 1. The shareholders of this corporation shall hold an annual meeting in each calendar year at such time and place, within or without the state of Minnesota, as may be designated by the Board of Directors, for the purpose of electing directors, and for the transaction only of such other business as is properly brought before the meeting in accordance with these Bylaws; provided, however, that the interval between two consecutive annual meetings shall not be more than fourteen (14) months nor less than ten (10) months. A notice setting out the time and place of the annual meeting shall be mailed by the secretary of the corporation, or his delegate, postage prepaid, to each shareholder of record at his address as it appears on the records of the corporation, or, if no such address appears, at his last known place of residence, at least ten (10) days prior to said annual meeting, but any shareholder may waive such annual notice by a signed waiver in writing. Section 2. At the annual meeting, the shareholders shall elect directors of the corporation and shall transact such other business as may properly come before them. To be properly brought before the meeting, business must be of a nature that is appropriate for consideration at an annual meeting and must be (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, or (ii) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (iii) otherwise properly brought before the meeting by a shareholder. In addition to any other applicable requirements, for business to be properly brought before the annual meeting by a shareholder, the shareholder must have given timely notice thereof in writing to the secretary of the corporation. To be timely, each such notice must be given, either by personal delivery or by United States mail, postage prepaid, to the secretary of the corporation, not less than fifty (50) days nor more than seventy-five (75) days prior to the meeting; provided, however, that in the event that less than sixty (60) days' notice or prior public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the day on which such notice of the date of the annual meeting was mailed or such public disclosure was made, whichever first occurs. Each such notice to the secretary shall set forth as to each matter the shareholder proposes to bring before the annual meeting (w) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (x) the name and address of record of the shareholder proposing such business, (y) the class or series (if any) and number of shares of the corporation which are owned by the shareholder, and (z) any material interest of the shareholder in such business. Notwithstanding anything in these Bylaws to the contrary, no business shall be *As amended through October 14, 1997 transacted at the annual meeting except in accordance with the procedures set forth in this Article; provided, however, that nothing in this Article shall be deemed to preclude discussion by any shareholder of any business properly brought before the annual meeting, in accordance with these Bylaws. Section 3. Special meetings of the shareholders may be called for any purpose or purposes at any time, by: (a) The chief executive officer; (b) The chief financial officer: (c) Two or more directors; (d) A shareholder or shareholders holding ten percent or more of the voting power of all shares entitled to vote, except that a special meeting for the purpose of considering any action to directly or indirectly facilitate or effect a business combination, including any action to change or otherwise affect the composition of the board of directors for that purpose, must be called by 25 percent or more of the voting power of all shares entitled to vote. Such meeting shall be called by mailing a notice thereof as above provided in the case of the annual meeting of shareholders, which notice shall state the purpose or purposes of the meeting. Section 4. At any shareholders' meeting, each shareholder shall be entitled to one (1) vote for each share of common stock standing in his name on the books of the corporation as of the record date. Any shareholder may vote either in person or by proxy. The presence in person or by proxy of the holders of a majority of the shares of common stock entitled to vote at any shareholders' meeting shall constitute a quorum for the transaction of business. If no quorum is present at any meeting, the shareholders present in person or by proxy may adjourn the meeting to such future time as they shall agree upon without further notice other than by announcement at the meeting at which such adjournment is taken. Section 5. At any shareholders' meeting for which there is a quorum present, the shareholders may conduct such business as may be on the agenda or otherwise proposed for such meeting, or any part of such business in the case of an adjournment. All or any part of the business not conducted at the initial meeting of shareholders may be conducted at any adjournments thereof, including any specific proposals on the agenda for such initial meeting for which there was no final disposition. A meeting of the shareholders at which there is a quorum can be adjourned as to all or part of the matters to be considered at the meeting upon motion by the person presiding at such meeting and by a majority vote of shares represented in person or by proxy at such meeting. Such adjournment shall be until a specific time and place, and the time and place for the reconvened meeting shall be announced at the meeting and reflected in the minutes thereof. In addition, if the adjourned date is less than ten (10) days after the date of the meeting at which an adjournment proposal was passed, a public announcement shall be made by the corporation as to the time and place for the reconvened meeting; or, if the adjourned date for the reconvened meeting is ten (10) days or more after the date of the meeting at which the adjournment proposal was passed, notice of the time and place of the reconvened meeting shall be sent by first class mail to all shareholders of record at least ten (10) days prior to such reconvened meeting. ARTICLE II Directors Section 1. The Board of Directors shall have the general management and control of all business and affairs of the corporation and shall exercise all the powers that may be exercised or performed by the corporation under the statutes, its Articles of Incorporation and its Bylaws. Section 2. (a) The Board of Directors shall consist of such number of directors, not less than three, the exact number to be fixed from time to time solely by resolution of the Board of Directors, acting by not less than a majority of the directors then in office. (b) The Board of Directors shall be divided into three classes, with the term of office of one class expiring each year. At the Annual Meeting of Shareholders in 1986, two directors of the first class shall be elected to hold office for a term expiring at the 1987 Annual Meeting, two directors of the second class shall be elected to hold office for a term expiring at the 1988 Annual Meeting, and one director of the third class shall be elected to hold office for a term expiring at the 1989 Annual Meeting. Commencing with the Annual meeting of Shareholders in 1987, each class of directors whose term shall then expire shall be elected to hold office for a three-year term. In the case of any vacancy on the Board of Directors, including a vacancy created by an increase in the number of directors, the vacancy shall be filled by election of the Board of Directors with the director so elected to serve for the remainder of the term of the director being replaced or, in the case of an additional director, for the remainder of the term of the class to which the director has been assigned. All directors shall continue in office until the election and qualification of their respective successors in office. When the number of directors is changed, any newly created directorships shall be so assigned among the classes by a majority of the directors then in office, though less than a quorum, as to make all classes as nearly equal in number as possible. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. (c) Any director or directors may be removed from office at any time, but only for cause and only by the affirmative vote of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock (as defined in Article XIII of the corporation's Articles of Incorporation), voting together as a single class. (d) In the event that the Board of Directors increases the number of directors or fills a vacancy on the Board in accordance with the provisions of paragraph (b) of this Section 2, the Board of Directors shall give written notice to the shareholders of the corporation of any increase in the number of directors and of pertinent information regarding any director so elected by the Board to fill a vacancy. Such written notice shall be effected by inclusion of such information in the next mailing to shareholders of the corporation following any such increase in the number of directors or election of a director to fill a vacancy by the Board. Section 3. Subject to the rights of holders of any class or series of stock having a preference over the common shares as to dividends or upon liquidation, nominations for the election of directors may be made by the Board of Directors or a committee to be appointed by the Board of Directors or by any shareholder entitled to vote generally in the election of directors. However, any shareholder entitled to vote generally in the election of directors may nominate one or more persons for election as directors at a meeting only if written notice of such shareholder's intent to make such nomination or nominations has been given, either by personal delivery or by United States mail, postage prepaid, to the secretary of the corporation not less than fifty (50) nor more than seventy-five (75) days prior to the meeting; provided, however, that in the event that less than sixty (60) days' notice or prior public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the day on which such notice of the date of meeting was mailed or such public disclosure was made, whichever first occurs. Each such notice to the secretary shall set forth: (i) the name and address of record of the shareholder who intends to make the nomination; (ii) a representation that the shareholder is a holder of record of shares of the corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice; (iii) the name, age, business and residence addresses, and principal occupation or employment of each nominee; (iv) a description of all arrangements or understandings between the shareholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the shareholder; (v) such other information regarding each nominee proposed by such shareholder as would be required to be included in a proxy statement filed pursuant to the proxy rules of the Securities and Exchange Commission; and (vi) the consent of each nominee to serve as a director of the corporation if so elected. The corporation may require any proposed nominee to furnish such other information as may reasonably be required by the corporation to determine the eligibility of such proposed nominee to serve as a director of the corporation. The presiding officer of the meeting may, if the facts warrant, determine that a nomination was not made in accordance with the foregoing procedure, and if he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded. Section 4. The Board of Directors may meet regularly at such time and place as it shall fix by resolution, and no notice of regular meetings shall be required. Special meetings of the Board of Directors may be called by the chairman of the board, the president or by any majority of directors by giving at least twenty-four (24) hours' notice to each of the other directors by mail, telephone, telegraph, or in person. Section 5. A majority of the directors shall constitute a quorum for the transaction of business. Any act which might have been taken at a meeting of the Board of Directors may be taken without a meeting if authorized in a writing signed by all of the directors, and any such action shall be as valid and effective in all respects as if taken by the Board at a regular meeting. Section 6. The Board of Directors shall fix and change, as it may from time to time determine, the compensation to be paid the president. The president shall fix and change the compensation to be paid the other officers of the corporation. See Article III. Section 7. The Board of Directors may, by unanimous affirmative action of the entire Board of Directors designate two (2) or more of their number to constitute an Executive Committee which, to the extent determined by the Board, shall have and exercise the authority of the Board in the management of the business of the corporation. Such Executive Committee shall act only in the interval between meetings of the Board and shall be subject at all times to the control and direction of the Board. ARTICLE III Officers Section 1. The officers of this corporation shall be a president, a treasurer a secretary and such vice presidents and other officers as may from time to time be elected by the Board of Directors. If a Chairman of the Board of Directors is elected, he shall have the status of an officer of the corporation. All officers shall be elected by the Board of Directors and shall serve at the pleasure of the Board of Directors. Any two (2) of the offices, except those of the president and vice president, may be held by the same person. Section 2. The president may fix and change, as he may from time to time determine, the compensation to be paid the officers, other than the president, and the employees of the corporation, subject to the power of the directors to fix and change the compensation of the officers. Section 3. The vice president, or executive vice president if there is more than one, shall perform the duties and assume the responsibilities of the president in the absence or inability to act of the president. In case of death, resignation or permanent disability of the president, the executive vice president shall act as president until the Board of Directors designates such new president. Section 4. The secretary shall keep a record of the minutes of the proceedings of meetings of directors and of shareholders, and shall give notice of such meetings as required in these Bylaws or by the Board of Directors. Section 5. The treasurer shall keep accounts of all monies and other assets of the corporation received or disbursed, shall deposit all monies and valuables in the name of and to, the credit of the corporation in such banks or depositories or with such custodians as may be authorized to receive the same by these Bylaws and by the Board of Directors, and shall render such accounts thereof as may be required by the Board of Directors, the president or the shareholders. Section 6. The Chairman of the Board of Directors, or the president if there be no Chairman, shall preside at all meetings of the Board of Directors and of the shareholders, shall make such reports to the Board and to the shareholders as may from time to time be required of him and shall have such other powers and perform such other duties as are incident to his office or as may be from time to time assigned to him by the Board of Directors. ARTICLE IV Office The principal office of the corporation shall be in the state of Minnesota. The corporation may also have an office or offices in such other places and in such other states as the Board of Directors may from time to time authorize and establish. ARTICLE V No Seal; Stock Certificates Section 1. The corporation shall have no corporate seal. Section 2. Stock certificates issued by the corporation shall be signed by any two (2) officers. When a certificate is signed by a transfer agent or registrar, the signature of any such officer may be facsimiled, engraved or printed. ARTICLE VI Closing of Stock Records or Fixing of Record Date The Board of Directors shall have power to close the stock records of the corporation for a period not to exceed sixty (60) days preceding the date of any meeting of shareholders or the date for payment of any dividend, or the date for the allotment of rights, or the date when any change or conversion or exchange of capital stock shall go into effect, or for a period not exceeding sixty (60) days in connection with obtaining the consent of shareholders for any purpose; provided, however, that in lieu of closing the stock records, the Board of Directors may fix in advance a date not exceeding sixty (60) days preceding the date of any meeting of shareholders, or the date for the payment of any dividend, or the date for the allotment of rights, or the date when any change or conversion or exchange of capital stock shall go into effect, or a date in connection with obtaining such consent of shareholders, or for the determination of shareholders entitled to receive payment of any such dividend or to receive any such allotment of rights or to exercise rights in respect of any such change, conversion or exchange of capital stock, or to give any such consent, as the case may be, and in such case only such shareholders shall be shareholders of record on the date so fixed shall be entitled to such notice of and to attend such meeting, or to receive payment of such dividend, or to receive such allotment of rights, or to exercise any rights, or to give such consent, as the case may be, notwithstanding the transfer of any stock on the books of the corporation after any such record date fixed as aforesaid. ARTICLE VII Indemnification Section 1. Definitions. (a) For purposes of this Article, the terms defined in this Section have the meanings given them. (b) "Corporation" includes a domestic or foreign corporation that was the predecessor of the corporation in a merger or other transaction in which the predecessor's existence ceased upon consummation of the transaction. (c) "Official capacity" means (1) with respect to a director, the position of director in the corporation, (2) with respect to a person other than a director, the elective or appointive office or position held by an officer, member of a committee of the Board, or the employment or agency relationship undertaken by an employee or agent of the corporation (3) with respect to a director, officer, employee or agent of the corporation who, while a director, officer, employee or agent of the corporation, is or was serving at the request of the corporation or whose duties in that position involve or involved service as a director, officer, partner, trustee, or agent of another organization or employee benefit plan, the position of that person as a director, officer, partner, trustee, employee or agent, as the case may be, of the other organization or employee benefit plan. (d) "Proceedings" means a threatened, pending or completed civil, criminal, administrative, arbitration or investigative proceeding, including a proceeding by or in the right of the corporation. (e) "Special legal counsel" means counsel who has not represented the corporation or a related corporation, or a director, officer, employee or agent whose indemnification is in issue. Section 2. Indemnification mandatory; standard. (a) Subject to the provisions of Section 4, the corporation shall indemnify a person made or threatened to be made a party to a proceeding by reason of the former or present official capacity of the person against judgments, penalties, fines, including without limitation, excise taxes assessed against the person with respect to an employee benefit plan, settlements and reasonable expenses, including attorneys' fees and disbursements, incurred by the person in connection with the proceeding, if, with respect to the acts or omissions of the person complained of in the proceeding, the person: (1) has not been indemnified by another organization or employee benefit plan for the same judgments, penalties, fines, including, without limitation, excise taxes assessed against the person with respect to an employee benefit plan, settlements, and reasonable expenses, including attorneys' fees and disbursements, incurred by the person in connection with the proceeding with respect to the same acts or omissions; (2) acted in good faith; (3) received no improper personal benefit and Minnesota Statutes, Section 302A.255, if applicable, has been satisfied; (4) in the case of a criminal proceeding, had no reasonable cause to believe the conduct was unlawful; and (5) in the case of acts or omissions occurring in the official capacity described in Section 1, paragraph (c), clause (1) or (2), reasonably believed that the conduct was in the best interests of the corporation, or in the case of acts or omissions occurring in the official capacity described in Section 1, paragraph (c), clause (3), reasonably believed that the conduct was not opposed to the best interests of the corporation. If the person's acts or omissions complained of in the proceeding relate to conduct as a director, officer, trustee, employee or agent of an employee benefit plan, the conduct is not considered to be opposed to the best interests of the corporation if the person reasonably believed that the conduct was in the best interests of the participants or beneficiaries of the employee benefit plan. (b) The termination of a proceeding by judgment order, settlement, conviction, or upon a plea of nolo contendere or its equivalent does not, of itself, establish that the person did not meet the criteria set forth in this Section 2. Section 3. Advances. Subject to the provisions of Section 4, if a person is made or threatened to be made a party to a proceeding, the person is entitled, upon written request to the corporation, to payment or reimbursement by the corporation of reasonable expenses, including attorneys' fees and disbursements, incurred by the person in advance of the final disposition of the proceeding, (a) upon receipt by the corporation of a written affirmation by the person of a good faith belief that the criteria for indemnification set forth in Section 2 have been satisfied and a written undertaking by the person to repay all amounts so paid or reimbursed by the corporation, if it is ultimately determined that the criteria for indemnification have not been satisfied, and (b) after a determination that the facts then known to those making the determination would not preclude indemnification under this Article. The written-undertaking required by clause (a) is an unlimited general obligation of the person making it, but need not be secured and shall be accepted without reference to financial ability to make the repayment. Section 4. Reimbursement to witness. The corporation shall reimburse expenses including attorneys' fees and disbursements, incurred by a person in connection with an appearance as a witness in a proceeding at a time when the person has not been made or threatened to be made a party to a proceeding. Section 5. Determination of eligibility. (a) All determinations whether indemnification of a person is required because the criteria set forth in Section 2 have been satisfied and whether a person is entitled to payment or reimbursement of expenses in advance of the final disposition of a proceeding as provided in Section 3 shall be made: (1) By the Board by a majority of a quorum. Directors who are at the time parties to the proceeding shall not be counted for determining either a majority or the presence of a quorum; (2) If a quorum under clause (1) cannot be obtained, by a majority of a Committee of the Board, consisting solely of two or more directors not at the time parties to the proceeding, duly designated to act in the matter by a majority of the full Board including directors who are parties; (3) If a determination is not made under clause (1) or (2), by special legal counsel, selected either by a majority of the Board or a committee by vote pursuant to clause (1) or (2) or, if the requisite quorum of the full Board cannot be obtained and the committee cannot be established, by a majority of the full Board including directors who are parties; (4) If a determination is not made under clauses (1) to (3), by the shareholders, excluding the votes of shares held by parties to the proceeding; or (5) If an adverse determination is made under clauses (1) to (4) or under paragraph (b), or if no determination is made under clauses (1) to (4) or under paragraph (b) within sixty (60) days after the termination of a proceeding or after a request for an advance of expenses, as the case may be, by a court in Minnesota, which may be the same court in which the proceeding involving the person's liability took place, upon application of the person and any notice the court requires. (b) With respect to a person who is not, and was not at the time of the acts or omissions complained of in the proceedings, a director, officer or person possessing, directly or indirectly, the power to direct or cause the direction of the management or policies of the corporation, the determination whether indemnification of this person is required because the criteria set forth in Section 2 have been satisfied and whether this person is entitled to payment or reimbursement of expenses in advance of the final disposition of a proceeding as provided in Section 3 may be made by an annually-appointed committee of the Board, having at least one member who is a director. The committee shall report at least annually to the Board concerning its actions. Section 6. Insurance. The corporation may purchase and maintain insurance on behalf of a person in that person's official capacity against any liability asserted against and incurred by the person in or arising from that capacity, whether or not the corporation would have been required to indemnify the person against the liability under the provisions of this Article. Section 7. Disclosure. The amount of any indemnification or advance paid pursuant to this Article and to whom and on whose behalf it was pa id shall be reported as part of the annual financial statements furnished to shareholders pursuant to Minnesota Statutes, Section 302A.463 covering the period when the indemnification or advance was paid or accrued under the accounting method of the corporation reflected in the financial statements. Section 8. Discretionary indemnification. Nothing in this Article VII shall be construed to limit the ability of the Board of Directors, to the extent permitted by applicable law, to indemnify any person or entity not described in this Article VII pursuant to, and to the extent described in, an agreement authorized in accordance with the provisions of Section 5(a) above, or as otherwise determined by the Board of Directors in its discretion. Furthermore, the Board of Directors may authorize written agreements between the Company and persons, whether or not described in this Article VII, to grant contractual rights to such persons as permitted by law. ARTICLE VIII Adoption and Amendment of Bylaws Section 1. The Board of Directors may alter or amend these Bylaws and may make or adopt additional Bylaws subject to the power of the Shareholders to change or repeal the Bylaws, except that the Board of Directors shall not make or alter any Bylaws fixing their qualifications, classifications or term of office, or reducing their number. Section 2. The shareholders may alter or amend these Bylaws and may make or adopt additional Bylaws by a majority vote at any annual meeting of the shareholders or at any special meeting called for that purpose, except as may be provided by Article IX or any other provisions of the Articles of Incorporation of the corporation. Certification The undersigned, _____________________________, Secretary of St. Jude Medical, Inc., a corporation duly incorporated under the laws of the state of Minnesota, hereby certifies that the Bylaws attached hereto are true and correct; as amended to date. Executed this _____ day of _________________, 19____. ------------------------------------- Secretary EX-27 3 FINANCIAL DATA SCHEDULE
5 9-MOS DEC-31-1997 JAN-01-1997 SEP-30-1997 22,311 149,601 255,430 7,776 240,057 730,656 455,446 142,621 1,466,636 257,812 0 0 0 9,182 970,142 1,466,636 745,035 745,035 272,114 272,114 0 (71) 10,804 77,519 27,325 50,194 0 0 0 50,194 .54 .54
-----END PRIVACY-ENHANCED MESSAGE-----